Dataset Information

Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause.

ABSTRACT: Lipid metabolism disorder is a common pathological manifestation of menopausal women, and is also an important risk factor for many diseases at this stage of life. Epidemiological studies have shown that high levels of follicle-stimulating hormone (FSH) in menopausal women are closely associated with changes in body composition, central obesity, and cognitive decline. Exogenous FSH causes growth and proliferation of adipose, whereas blockage of the FSH signaling pathway leads to decline in adipose. Mechanistically, FSH, FSH receptor (FSHR), G protein coupling, gene mutation and other pathways are involved in adipogenesis and cognitive impairment. Here, we review the critical role and potential interactions of FSH in adipogenesis and cognitive impairment in menopausal women. Further understanding of the exact mechanisms of FSH aggravating obesity and cognitive impairment may provide a new perspective for promoting healthy aging in menopausal women.

SUBMITTER: Mao L

PROVIDER: S-EPMC9760686 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause.

Mao Liwei L Wang Lian L Bennett Samuel S Xu Jiake J Zou Jun J

Frontiers in physiology 20221205

Lipid metabolism disorder is a common pathological manifestation of menopausal women, and is also an important risk factor for many diseases at this stage of life. Epidemiological studies have shown that high levels of follicle-stimulating hormone (FSH) in menopausal women are closely associated with changes in body composition, central obesity, and cognitive decline. Exogenous FSH causes growth and proliferation of adipose, whereas blockage of the FSH signaling pathway leads to decline in adipo ...[more]

PMID: 36545281

Similar Datasets

Project description:ObjectiveTo establish conditions for effective hypothalamic suppression in women with normal and high body mass index (BMI) and test the hypothesis that intravenous (IV) administration of pulsatile recombinant follicle-stimulating hormone (rFSH) can overcome the clinically evident dysfunctional pituitary-ovarian axis in women with obesity.DesignProspective interventional study.SettingAcademic medical center.Patient(s)Twenty-seven normal-weight women and 27 women with obesity, who were eumenorrheic and aged 21-39 years.Intervention(s)Two-day frequent blood sampling study, in early follicular phase, before and after cetrorelix suppression of gonadotropins and exogenous pulsatile IV rFSH administration.Main outcome measure(s)Serum inhibin B and estradiol (E2) levels (basal and rFSH stimulated).Result(s)A modified gonadotropin-releasing hormone antagonism protocol effectively suppressed production of endogenous gonadotropins in women with normal and high BMIs, providing a model to address the functional role of FSH in the hypothalamic-pituitary-ovarian axis. The IV rFSH treatment resulted in equivalent serum levels and pharmacodynamics in normal-weight women and those with obesity. However, women with obesity exhibited reduced basal levels of inhibin B and E2 and a significantly decreased response to FSH stimulation. The BMI was inversely correlated with serum inhibin B and E2. In spite of this observed deficit in ovarian function, pulsatile IV rFSH treatment in women with obesity resulted in E2 and inhibin B levels comparable with those in normal-weight women, in the absence of exogenous FSH stimulation.Conclusion(s)Despite normalization of FSH levels and pulsatility by exogenous IV administration, women with obesity demonstrate ovarian dysfunction with respect to E2 and inhibin B secretion. Pulsatile FSH can partially correct the relative hypogonadotropic hypogonadism of obesity, thereby providing a potential treatment strategy to mitigate some of the adverse effects of high BMI on fertility, assisted reproduction, and pregnancy outcomes.Clinical trial registration numberClinicalTrials.gov #NCT02478775.

Dataset Information

Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause.

Publications

Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets